tirzepatide testing Weight-Loss Drug Zepbound Is Being Tested as a Treatment for Long Covid Each generation of GLP-1 agonist

Hair loss emerged as a concern in some participants, consistent with what researchers observe across the GLP-1 agonist class

Timing can be important to maximize the benefits and minimize any potential risks

Weight management concerns should be evaluated by a qualified healthcare professional

Targeting more than one may pave the way to greater weight loss. A Well-Controlled Comparison The clinical trial was sponsored by Eli Lilly, the maker of tirzepatide, and included researchers from NewYork-Presbyterian, the University of Texas, UCLA, University College Dublin, and 32 clinical sites across the United States and Puerto Rico